DNA RNA and Cells

13 Oct 2021 Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01
12 Oct 2021 Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
12 Oct 2021 Repertoire Immune Medicines Announces First Patient Dosed in Phase 1 Clinical Study of RPTR-168 (PRIME IL-12) for Relapsed or Refractory HPV-16-Positive Tumors
12 Oct 2021 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
11 Oct 2021 4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
10 Oct 2021 Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
10 Oct 2021 REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
09 Oct 2021 Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
09 Oct 2021 Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
08 Oct 2021 CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
08 Oct 2021 Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
06 Oct 2021 TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy
06 Oct 2021 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease
06 Oct 2021 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
06 Oct 2021 Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
04 Oct 2021 Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
04 Oct 2021 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
04 Oct 2021 REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
04 Oct 2021 Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek
04 Oct 2021 U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
04 Oct 2021 Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
01 Oct 2021 Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
30 Sep 2021 Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
27 Sep 2021 GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.
27 Sep 2021 JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top